I reported previously (see here) on Jerusalem-based immunotherapy company Enlivex Therapeutics. Enlivex has merged with Tel Aviv-headquartered Bioblast (see here), which is developing treatments for rare genetic diseases.
https://www.calcalistech.com/ctech/articles/0,7340,L-3759270,00.html